Abstract 2081
Background
Durvalumab gained FDA approval for locally advanced or metastatic UC following failure of platinum-based chemotherapy (CTx) based on the open-label, single arm study 1108. Real-world evidence can be used to enable comparative analyses by matching patients’ baseline characteristics from independent datasets. Overall survival (OS) of patients on durvalumab vs CTx was evaluated by comparing patients in the phase 1/2 study 1108 (NCT01693562) with a real-world dataset.
Methods
Data from patients on durvalumab were compared with data from patients in the Flatiron oncology electronic medical record database treated with physician’s choice of 2nd line CTx. All patients had progressed following platinum-based CTx. Patients were matched on propensity score to adjust for differences in baseline demographics and disease characteristics. Treatment effect for OS was estimated using Cox proportional hazards models. Prognostic impact of expression of programmed cell death ligand-1 (PD-L1) (≥25% of tumour cells [TC]/immune cells [IC] [high] or < 25% TC/IC [low/negative]) on OS was also evaluated. As PD-L1 expression was only available for patients in study 1108, PD-L1 subgroups were compared to otherwise-matched CTx patients.
Results
After adjustment for baseline differences between the 2 groups, durvalumab demonstrated a statistically significant improvement in OS vs CTx (n = 158/arm; HR = 0.634, 95% CI 0.479-0.839; median OS 11.2 vs 8.19 months). Treatment effect of durvalumab was greater in the PD-L1 high subgroup (n = 91 /arm; HR = 0.434, 95% CI 0.292-0.645; median OS 19.9 vs 7.84 months) vs matched CTx patients. There was no significant difference in OS for the PD-L1 low/negative subgroup for durvalumab vs CTx (n = 74/arm; HR = 0.989, 95% CI 0.679-1.440; median OS 4.86 vs 7.20 months).
Conclusions
This indirect, match-adjusted comparison of durvalumab vs CTx suggests that durvalumab provides a statistically significant improvement in OS vs CTx for patients with locally advanced or metastatic UC who progressed after platinum-based CTx; treatment effect was more pronounced in the PD-L1 high subgroup vs the PD-L1 low/negative subgroup.
Clinical trial identification
CD-ON-MEDI4736-1108 (NCT01693562).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Editorial Acknowledgement
Editorial support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Anne-Marie Manwaring of Parexel, and was funded by AstraZeneca.
Disclosure
C.K. Hoyle, A.B. Klein, K.A. Patel, N. Shire, H. Wang, M. Ouwens: Employee and shareholder of AstraZeneca. B.C. Chu: Employee of Real-world Evidence, Evidera. B.L. Nordstrom: Employee of Real-world Evidence, Evidera. L. Horne: Contractor and Shareholder: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract